Shopping Cart 0
Cart Subtotal
AED 0

Generics Top 5 Emerging Markets Industry Guide 2013-2022

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 3652

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 7303

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 10955
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Generics Top 5 Emerging Markets Industry Guide 2013-2022

Summary

The Emerging 5 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Questions Answered:

- What was the size of the emerging five generics market by value in 2017?

- What will be the size of the emerging five generics market in 2022?

- What factors are affecting the strength of competition in the emerging five generics market?

- How has the market performed over the last five years?

- How large is the emerging five generics market in relation to its regional counterparts?

Scope

Essential resource for top-line data and analysis covering the emerging five generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

- These countries contributed USD 88,890.2 million to the global generics industry in 2017, with a compound annual growth rate (CAGR) of 11% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of USD 1,26,524.6 million in 2022, with a CAGR of 7.3% over the 2017-22 period.

- Within the generics industry, China is the leading country among the top 5 emerging nations, with market revenues of USD 61,399.8 million in 2017. This was followed by India and Brazil with a value of USD 14,395.1 and USD 6,435.8 million, respectively.

- China is expected to lead the generics industry in the top five emerging nations, with a value of USD 86,778.1 million in 2022, followed by India and Brazil with expected values of USD 20,551.5 and USD 9,201.9 million, respectively.

Reasons to buy

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging five generics market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging five generics market

- Leading company profiles reveal details of key generics market players' emerging five operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the emerging five generics market with five year forecasts by both value and volume

- Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country

READ MORE

Table Of Content

Scope

Table of Contents

Introduction 11

What is this report about? 11

Who is the target reader? 11

How to use this report 11

Definitions 11

Top 5 Emerging Countries Generics 12

Industry Outlook 12

Generics in South Africa 15

Market Overview 15

Market Data 16

Market Segmentation 18

Market outlook 19

Five forces analysis 21

Macroeconomic indicators 27

Generics in Brazil 29

Market Overview 29

Market Data 30

Market Segmentation 32

Market outlook 33

Five forces analysis 35

Macroeconomic indicators 41

Generics in China 43

Market Overview 43

Market Data 44

Market Segmentation 46

Market outlook 47

Five forces analysis 49

Macroeconomic indicators 56

Generics in India 58

Market Overview 58

Market Data 59

Market Segmentation 61

Market outlook 62

Five forces analysis 64

Macroeconomic indicators 70

Generics in Mexico 72

Market Overview 72

Market Data 73

Market Segmentation 75

Market outlook 76

Five forces analysis 78

Macroeconomic indicators 84

Company Profiles 86

Leading Companies 86

Appendix 130

Methodology 130

About MarketLine 131


List Of Figure

List of Figures

Figure 1: Top 5 emerging countries generics industry, revenue (USD m), 2013-22

Figure 2: Top 5 emerging countries generics industry, revenue (USD m), 2013-17

Figure 3: Top 5 emerging countries generics industry forecast, revenue (USD m), 2017-22

Figure 4: South Africa generics market value: USD million, 2013-17

Figure 5: South Africa generics market volume: % of total pharma, 2013-17

Figure 6: South Africa generics market geography segmentation: % share, by value, 2017

Figure 7: South Africa generics market value forecast: USD million, 2017-22

Figure 8: South Africa generics market volume forecast: % of total pharma, 2017-22

Figure 9: Forces driving competition in the generics market in South Africa, 2017

Figure 10: Drivers of buyer power in the generics market in South Africa, 2017

Figure 11: Drivers of supplier power in the generics market in South Africa, 2017

Figure 12: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2017

Figure 13: Factors influencing the threat of substitutes in the generics market in South Africa, 2017

Figure 14: Drivers of degree of rivalry in the generics market in South Africa, 2017

Figure 15: Brazil generics market value: USD million, 2013-17

Figure 16: Brazil generics market volume: % of total pharma, 2013-17

Figure 17: Brazil generics market geography segmentation: % share, by value, 2017

Figure 18: Brazil generics market value forecast: USD million, 2017-22

Figure 19: Brazil generics market volume forecast: % of total pharma, 2017-22

Figure 20: Forces driving competition in the generics market in Brazil, 2017

Figure 21: Drivers of buyer power in the generics market in Brazil, 2017

Figure 22: Drivers of supplier power in the generics market in Brazil, 2017

Figure 23: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2017

Figure 24: Factors influencing the threat of substitutes in the generics market in Brazil, 2017

Figure 25: Drivers of degree of rivalry in the generics market in Brazil, 2017

Figure 26: China generics market value: USD billion, 2013-17

Figure 27: China generics market volume: % of total pharma, 2013-17

Figure 28: China generics market geography segmentation: % share, by value, 2017

Figure 29: China generics market value forecast: USD billion, 2017-22

Figure 30: China generics market volume forecast: % of total pharma, 2017-22

Figure 31: Forces driving competition in the generics market in China, 2017

Figure 32: Drivers of buyer power in the generics market in China, 2017

Figure 33: Drivers of supplier power in the generics market in China, 2017

Figure 34: Factors influencing the likelihood of new entrants in the generics market in China, 2017

Figure 35: Factors influencing the threat of substitutes in the generics market in China, 2017

Figure 36: Drivers of degree of rivalry in the generics market in China, 2017

Figure 37: India generics market value: USD million, 2013-17

Figure 38: India generics market volume: % of total pharma, 2013-17

Figure 39: India generics market geography segmentation: % share, by value, 2017

Figure 40: India generics market value forecast: USD million, 2017-22

Figure 41: India generics market volume forecast: % of total pharma, 2017-22

Figure 42: Forces driving competition in the generics market in India, 2017

Figure 43: Drivers of buyer power in the generics market in India, 2017

Figure 44: Drivers of supplier power in the generics market in India, 2017

Figure 45: Factors influencing the likelihood of new entrants in the generics market in India, 2017

Figure 46: Factors influencing the threat of substitutes in the generics market in India, 2017

Figure 47: Drivers of degree of rivalry in the generics market in India, 2017

Figure 48: Mexico generics market value: USD million, 2013-17

Figure 49: Mexico generics market volume: % of total pharma, 2013-17

Figure 50: Mexico generics market geography segmentation: % share, by value, 2017

Figure 51: Mexico generics market value forecast: USD million, 2017-22

Figure 52: Mexico generics market volume forecast: % of total pharma, 2017-22

Figure 53: Forces driving competition in the generics market in Mexico, 2017

Figure 54: Drivers of buyer power in the generics market in Mexico, 2017

Figure 55: Drivers of supplier power in the generics market in Mexico, 2017

Figure 56: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2017

Figure 57: Factors influencing the threat of substitutes in the generics market in Mexico, 2017

Figure 58: Drivers of degree of rivalry in the generics market in Mexico, 2017

Figure 59: Adcock Ingram: revenues & profitability

Figure 60: Adcock Ingram: assets & liabilities

Figure 61: Aspen Pharmacare Holdings Ltd: revenues & profitability

Figure 62: Aspen Pharmacare Holdings Ltd: assets & liabilities

Figure 63: Novartis AG: revenues & profitability

Figure 64: Novartis AG: assets & liabilities

Figure 65: Sanofi SA: revenues & profitability

Figure 66: Sanofi SA: assets & liabilities

Figure 67: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability

Figure 68: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

Figure 69: Mylan N.V.: revenues & profitability

Figure 70: Mylan N.V.: assets & liabilities

Figure 71: Aurobindo Pharma Limited: revenues & profitability

Figure 72: Aurobindo Pharma Limited: assets & liabilities

Figure 73: Cipla Limited: revenues & profitability

Figure 74: Cipla Limited: assets & liabilities

Figure 75: Lupin Ltd: revenues & profitability

Figure 76: Lupin Ltd: assets & liabilities

Figure 77: Sun Pharmaceutical Industries Ltd: revenues & profitability

Figure 78: Sun Pharmaceutical Industries Ltd: assets & liabilities

Figure 79: Pfizer Inc.: revenues & profitability

Figure 80: Pfizer Inc.: assets & liabilities

Figure 81: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 82: Teva Pharmaceutical Industries Limited: assets & liabilities


List Of Table

List of Tables

Table 1: Top 5 emerging countries generics industry, revenue (USD m), 2013-22

Table 2: Top 5 emerging countries generics industry, revenue (USD m), 2013-17

Table 3: Top 5 emerging countries generics industry forecast, revenue (USD m), 2017-22

Table 4: South Africa generics market value: USD million, 2013-17

Table 5: South Africa generics market volume: % of total pharma, 2013-17

Table 6: South Africa generics market geography segmentation: USD million, 2017

Table 7: South Africa generics market value forecast: USD million, 2017-22

Table 8: South Africa generics market volume forecast: % of total pharma, 2017-22

Table 9: South Africa size of population (million), 2013-17

Table 10: South Africa gdp (constant 2005 prices, USD billion), 2013-17

Table 11: South Africa gdp (current prices, USD billion), 2013-17

Table 12: South Africa inflation, 2013-17

Table 13: South Africa consumer price index (absolute), 2013-17

Table 14: South Africa exchange rate, 2013-17

Table 15: Brazil generics market value: USD million, 2013-17

Table 16: Brazil generics market volume: % of total pharma, 2013-17

Table 17: Brazil generics market geography segmentation: USD million, 2017

Table 18: Brazil generics market value forecast: USD million, 2017-22

Table 19: Brazil generics market volume forecast: % of total pharma, 2017-22

Table 20: Brazil size of population (million), 2013-17

Table 21: Brazil gdp (constant 2005 prices, USD billion), 2013-17

Table 22: Brazil gdp (current prices, USD billion), 2013-17

Table 23: Brazil inflation, 2013-17

Table 24: Brazil consumer price index (absolute), 2013-17

Table 25: Brazil exchange rate, 2013-17

Table 26: China generics market value: USD billion, 2013-17

Table 27: China generics market volume: % of total pharma, 2013-17

Table 28: China generics market geography segmentation: USD billion, 2017

Table 29: China generics market value forecast: USD billion, 2017-22

Table 30: China generics market volume forecast: % of total pharma, 2017-22

Table 31: China size of population (million), 2013-17

Table 32: China gdp (constant 2005 prices, USD billion), 2013-17

Table 33: China gdp (current prices, USD billion), 2013-17

Table 34: China inflation, 2013-17

Table 35: China consumer price index (absolute), 2013-17

Table 36: China exchange rate, 2013-17

Table 37: India generics market value: USD million, 2013-17

Table 38: India generics market volume: % of total pharma, 2013-17

Table 39: India generics market geography segmentation: USD million, 2017

Table 40: India generics market value forecast: USD million, 2017-22

Table 41: India generics market volume forecast: % of total pharma, 2017-22

Table 42: India size of population (million), 2013-17

Table 43: India gdp (constant 2005 prices, USD billion), 2013-17

Table 44: India gdp (current prices, USD billion), 2013-17

Table 45: India inflation, 2013-17

Table 46: India consumer price index (absolute), 2013-17

Table 47: India exchange rate, 2013-17

Table 48: Mexico generics market value: USD million, 2013-17

Table 49: Mexico generics market volume: % of total pharma, 2013-17

Table 50: Mexico generics market geography segmentation: USD million, 2017

Table 51: Mexico generics market value forecast: USD million, 2017-22

Table 52: Mexico generics market volume forecast: % of total pharma, 2017-22

Table 53: Mexico size of population (million), 2013-17

Table 54: Mexico gdp (constant 2005 prices, USD billion), 2013-17

Table 55: Mexico gdp (current prices, USD billion), 2013-17

Table 56: Mexico inflation, 2013-17

Table 57: Mexico consumer price index (absolute), 2013-17

Table 58: Mexico exchange rate, 2013-17

Table 59: Adcock Ingram: key facts

Table 60: Adcock Ingram: key financials (USD )

Table 61: Adcock Ingram: key financials (ZAR)

Table 62: Adcock Ingram: key financial ratios

Table 63: Aspen Pharmacare Holdings Ltd: key facts

Table 64: Aspen Pharmacare Holdings Ltd: key financials (USD )

Table 65: Aspen Pharmacare Holdings Ltd: key financials (ZAR)

Table 66: Aspen Pharmacare Holdings Ltd: key financial ratios

Table 67: Novartis AG: key facts

Table 68: Novartis AG: key financials (USD )

Table 69: Novartis AG: key financial ratios

Table 70: Ache Laboratorios Farmaceuticos SA: key facts

Table 71: EMS SA: key facts

Table 72: Eurofarma Laboratorios SA: key facts

Table 73: Sanofi SA: key facts

Table 74: Sanofi SA: key financials (USD )

Table 75: Sanofi SA: key financials (EUR)

Table 76: Sanofi SA: key financial ratios

Table 77: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts

Table 78: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (USD )

Table 79: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)

Table 80: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios

Table 81: Mylan N.V.: key facts

Table 82: Mylan N.V.: key financials (USD )

Table 83: Mylan N.V.: key financial ratios

Table 84: Aurobindo Pharma Limited: key facts

Table 85: Aurobindo Pharma Limited: key financials (USD )

Table 86: Aurobindo Pharma Limited: key financials (Rs.)

Table 87: Aurobindo Pharma Limited: key financial ratios

Table 88: Cipla Limited: key facts

Table 89: Cipla Limited: key financials (USD )

Table 90: Cipla Limited: key financials (Rs.)

Table 91: Cipla Limited: key financial ratios

Table 92: Lupin Ltd: key facts

Table 93: Lupin Ltd: key financials (USD )

Table 94: Lupin Ltd: key financials (Rs.)

Table 95: Lupin Ltd: key financial ratios

Table 96: Sun Pharmaceutical Industries Ltd: key facts

Table 97: Sun Pharmaceutical Industries Ltd: key financials (USD )

Table 98: Sun Pharmaceutical Industries Ltd: key financials (Rs.)

Table 99: Sun Pharmaceutical Industries Ltd: key financial ratios

Table 100: Apotex, Inc.: key facts

Table 101: Pfizer Inc.: key facts

Table 102: Pfizer Inc.: key financials (USD )

Table 103: Pfizer Inc.: key financial ratios

Table 104: Teva Pharmaceutical Industries Limited: key facts

Table 105: Teva Pharmaceutical Industries Limited: key financials (USD )

Table 106: Teva Pharmaceutical Industries Limited: key financial ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

MarketLine, Pharmaceuticals and Healthcare, Generics , Emerging Markets

Generics Top 5 Emerging Markets Industry Guide 2013-2022

Summary

The Emerging 5 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Questions Answered:

- What was the size of the emerging five generics market by value in 2017?

- What will be the size of the emerging five generics market in 2022?

- What factors are affecting the strength of competition in the emerging five generics market?

- How has the market performed over the last five years?

- How large is the emerging five generics market in relation to its regional counterparts?

Scope

Essential resource for top-line data and analysis covering the emerging five generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

- These countries contributed USD 88,890.2 million to the global generics industry in 2017, with a compound annual growth rate (CAGR) of 11% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of USD 1,26,524.6 million in 2022, with a CAGR of 7.3% over the 2017-22 period.

- Within the generics industry, China is the leading country among the top 5 emerging nations, with market revenues of USD 61,399.8 million in 2017. This was followed by India and Brazil with a value of USD 14,395.1 and USD 6,435.8 million, respectively.

- China is expected to lead the generics industry in the top five emerging nations, with a value of USD 86,778.1 million in 2022, followed by India and Brazil with expected values of USD 20,551.5 and USD 9,201.9 million, respectively.

Reasons to buy

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging five generics market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging five generics market

- Leading company profiles reveal details of key generics market players' emerging five operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the emerging five generics market with five year forecasts by both value and volume

- Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country

READ MORE

Scope

Table of Contents

Introduction 11

What is this report about? 11

Who is the target reader? 11

How to use this report 11

Definitions 11

Top 5 Emerging Countries Generics 12

Industry Outlook 12

Generics in South Africa 15

Market Overview 15

Market Data 16

Market Segmentation 18

Market outlook 19

Five forces analysis 21

Macroeconomic indicators 27

Generics in Brazil 29

Market Overview 29

Market Data 30

Market Segmentation 32

Market outlook 33

Five forces analysis 35

Macroeconomic indicators 41

Generics in China 43

Market Overview 43

Market Data 44

Market Segmentation 46

Market outlook 47

Five forces analysis 49

Macroeconomic indicators 56

Generics in India 58

Market Overview 58

Market Data 59

Market Segmentation 61

Market outlook 62

Five forces analysis 64

Macroeconomic indicators 70

Generics in Mexico 72

Market Overview 72

Market Data 73

Market Segmentation 75

Market outlook 76

Five forces analysis 78

Macroeconomic indicators 84

Company Profiles 86

Leading Companies 86

Appendix 130

Methodology 130

About MarketLine 131


List Of Figure

List of Figures

Figure 1: Top 5 emerging countries generics industry, revenue (USD m), 2013-22

Figure 2: Top 5 emerging countries generics industry, revenue (USD m), 2013-17

Figure 3: Top 5 emerging countries generics industry forecast, revenue (USD m), 2017-22

Figure 4: South Africa generics market value: USD million, 2013-17

Figure 5: South Africa generics market volume: % of total pharma, 2013-17

Figure 6: South Africa generics market geography segmentation: % share, by value, 2017

Figure 7: South Africa generics market value forecast: USD million, 2017-22

Figure 8: South Africa generics market volume forecast: % of total pharma, 2017-22

Figure 9: Forces driving competition in the generics market in South Africa, 2017

Figure 10: Drivers of buyer power in the generics market in South Africa, 2017

Figure 11: Drivers of supplier power in the generics market in South Africa, 2017

Figure 12: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2017

Figure 13: Factors influencing the threat of substitutes in the generics market in South Africa, 2017

Figure 14: Drivers of degree of rivalry in the generics market in South Africa, 2017

Figure 15: Brazil generics market value: USD million, 2013-17

Figure 16: Brazil generics market volume: % of total pharma, 2013-17

Figure 17: Brazil generics market geography segmentation: % share, by value, 2017

Figure 18: Brazil generics market value forecast: USD million, 2017-22

Figure 19: Brazil generics market volume forecast: % of total pharma, 2017-22

Figure 20: Forces driving competition in the generics market in Brazil, 2017

Figure 21: Drivers of buyer power in the generics market in Brazil, 2017

Figure 22: Drivers of supplier power in the generics market in Brazil, 2017

Figure 23: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2017

Figure 24: Factors influencing the threat of substitutes in the generics market in Brazil, 2017

Figure 25: Drivers of degree of rivalry in the generics market in Brazil, 2017

Figure 26: China generics market value: USD billion, 2013-17

Figure 27: China generics market volume: % of total pharma, 2013-17

Figure 28: China generics market geography segmentation: % share, by value, 2017

Figure 29: China generics market value forecast: USD billion, 2017-22

Figure 30: China generics market volume forecast: % of total pharma, 2017-22

Figure 31: Forces driving competition in the generics market in China, 2017

Figure 32: Drivers of buyer power in the generics market in China, 2017

Figure 33: Drivers of supplier power in the generics market in China, 2017

Figure 34: Factors influencing the likelihood of new entrants in the generics market in China, 2017

Figure 35: Factors influencing the threat of substitutes in the generics market in China, 2017

Figure 36: Drivers of degree of rivalry in the generics market in China, 2017

Figure 37: India generics market value: USD million, 2013-17

Figure 38: India generics market volume: % of total pharma, 2013-17

Figure 39: India generics market geography segmentation: % share, by value, 2017

Figure 40: India generics market value forecast: USD million, 2017-22

Figure 41: India generics market volume forecast: % of total pharma, 2017-22

Figure 42: Forces driving competition in the generics market in India, 2017

Figure 43: Drivers of buyer power in the generics market in India, 2017

Figure 44: Drivers of supplier power in the generics market in India, 2017

Figure 45: Factors influencing the likelihood of new entrants in the generics market in India, 2017

Figure 46: Factors influencing the threat of substitutes in the generics market in India, 2017

Figure 47: Drivers of degree of rivalry in the generics market in India, 2017

Figure 48: Mexico generics market value: USD million, 2013-17

Figure 49: Mexico generics market volume: % of total pharma, 2013-17

Figure 50: Mexico generics market geography segmentation: % share, by value, 2017

Figure 51: Mexico generics market value forecast: USD million, 2017-22

Figure 52: Mexico generics market volume forecast: % of total pharma, 2017-22

Figure 53: Forces driving competition in the generics market in Mexico, 2017

Figure 54: Drivers of buyer power in the generics market in Mexico, 2017

Figure 55: Drivers of supplier power in the generics market in Mexico, 2017

Figure 56: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2017

Figure 57: Factors influencing the threat of substitutes in the generics market in Mexico, 2017

Figure 58: Drivers of degree of rivalry in the generics market in Mexico, 2017

Figure 59: Adcock Ingram: revenues & profitability

Figure 60: Adcock Ingram: assets & liabilities

Figure 61: Aspen Pharmacare Holdings Ltd: revenues & profitability

Figure 62: Aspen Pharmacare Holdings Ltd: assets & liabilities

Figure 63: Novartis AG: revenues & profitability

Figure 64: Novartis AG: assets & liabilities

Figure 65: Sanofi SA: revenues & profitability

Figure 66: Sanofi SA: assets & liabilities

Figure 67: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability

Figure 68: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

Figure 69: Mylan N.V.: revenues & profitability

Figure 70: Mylan N.V.: assets & liabilities

Figure 71: Aurobindo Pharma Limited: revenues & profitability

Figure 72: Aurobindo Pharma Limited: assets & liabilities

Figure 73: Cipla Limited: revenues & profitability

Figure 74: Cipla Limited: assets & liabilities

Figure 75: Lupin Ltd: revenues & profitability

Figure 76: Lupin Ltd: assets & liabilities

Figure 77: Sun Pharmaceutical Industries Ltd: revenues & profitability

Figure 78: Sun Pharmaceutical Industries Ltd: assets & liabilities

Figure 79: Pfizer Inc.: revenues & profitability

Figure 80: Pfizer Inc.: assets & liabilities

Figure 81: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 82: Teva Pharmaceutical Industries Limited: assets & liabilities


List Of Table

List of Tables

Table 1: Top 5 emerging countries generics industry, revenue (USD m), 2013-22

Table 2: Top 5 emerging countries generics industry, revenue (USD m), 2013-17

Table 3: Top 5 emerging countries generics industry forecast, revenue (USD m), 2017-22

Table 4: South Africa generics market value: USD million, 2013-17

Table 5: South Africa generics market volume: % of total pharma, 2013-17

Table 6: South Africa generics market geography segmentation: USD million, 2017

Table 7: South Africa generics market value forecast: USD million, 2017-22

Table 8: South Africa generics market volume forecast: % of total pharma, 2017-22

Table 9: South Africa size of population (million), 2013-17

Table 10: South Africa gdp (constant 2005 prices, USD billion), 2013-17

Table 11: South Africa gdp (current prices, USD billion), 2013-17

Table 12: South Africa inflation, 2013-17

Table 13: South Africa consumer price index (absolute), 2013-17

Table 14: South Africa exchange rate, 2013-17

Table 15: Brazil generics market value: USD million, 2013-17

Table 16: Brazil generics market volume: % of total pharma, 2013-17

Table 17: Brazil generics market geography segmentation: USD million, 2017

Table 18: Brazil generics market value forecast: USD million, 2017-22

Table 19: Brazil generics market volume forecast: % of total pharma, 2017-22

Table 20: Brazil size of population (million), 2013-17

Table 21: Brazil gdp (constant 2005 prices, USD billion), 2013-17

Table 22: Brazil gdp (current prices, USD billion), 2013-17

Table 23: Brazil inflation, 2013-17

Table 24: Brazil consumer price index (absolute), 2013-17

Table 25: Brazil exchange rate, 2013-17

Table 26: China generics market value: USD billion, 2013-17

Table 27: China generics market volume: % of total pharma, 2013-17

Table 28: China generics market geography segmentation: USD billion, 2017

Table 29: China generics market value forecast: USD billion, 2017-22

Table 30: China generics market volume forecast: % of total pharma, 2017-22

Table 31: China size of population (million), 2013-17

Table 32: China gdp (constant 2005 prices, USD billion), 2013-17

Table 33: China gdp (current prices, USD billion), 2013-17

Table 34: China inflation, 2013-17

Table 35: China consumer price index (absolute), 2013-17

Table 36: China exchange rate, 2013-17

Table 37: India generics market value: USD million, 2013-17

Table 38: India generics market volume: % of total pharma, 2013-17

Table 39: India generics market geography segmentation: USD million, 2017

Table 40: India generics market value forecast: USD million, 2017-22

Table 41: India generics market volume forecast: % of total pharma, 2017-22

Table 42: India size of population (million), 2013-17

Table 43: India gdp (constant 2005 prices, USD billion), 2013-17

Table 44: India gdp (current prices, USD billion), 2013-17

Table 45: India inflation, 2013-17

Table 46: India consumer price index (absolute), 2013-17

Table 47: India exchange rate, 2013-17

Table 48: Mexico generics market value: USD million, 2013-17

Table 49: Mexico generics market volume: % of total pharma, 2013-17

Table 50: Mexico generics market geography segmentation: USD million, 2017

Table 51: Mexico generics market value forecast: USD million, 2017-22

Table 52: Mexico generics market volume forecast: % of total pharma, 2017-22

Table 53: Mexico size of population (million), 2013-17

Table 54: Mexico gdp (constant 2005 prices, USD billion), 2013-17

Table 55: Mexico gdp (current prices, USD billion), 2013-17

Table 56: Mexico inflation, 2013-17

Table 57: Mexico consumer price index (absolute), 2013-17

Table 58: Mexico exchange rate, 2013-17

Table 59: Adcock Ingram: key facts

Table 60: Adcock Ingram: key financials (USD )

Table 61: Adcock Ingram: key financials (ZAR)

Table 62: Adcock Ingram: key financial ratios

Table 63: Aspen Pharmacare Holdings Ltd: key facts

Table 64: Aspen Pharmacare Holdings Ltd: key financials (USD )

Table 65: Aspen Pharmacare Holdings Ltd: key financials (ZAR)

Table 66: Aspen Pharmacare Holdings Ltd: key financial ratios

Table 67: Novartis AG: key facts

Table 68: Novartis AG: key financials (USD )

Table 69: Novartis AG: key financial ratios

Table 70: Ache Laboratorios Farmaceuticos SA: key facts

Table 71: EMS SA: key facts

Table 72: Eurofarma Laboratorios SA: key facts

Table 73: Sanofi SA: key facts

Table 74: Sanofi SA: key financials (USD )

Table 75: Sanofi SA: key financials (EUR)

Table 76: Sanofi SA: key financial ratios

Table 77: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts

Table 78: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (USD )

Table 79: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)

Table 80: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios

Table 81: Mylan N.V.: key facts

Table 82: Mylan N.V.: key financials (USD )

Table 83: Mylan N.V.: key financial ratios

Table 84: Aurobindo Pharma Limited: key facts

Table 85: Aurobindo Pharma Limited: key financials (USD )

Table 86: Aurobindo Pharma Limited: key financials (Rs.)

Table 87: Aurobindo Pharma Limited: key financial ratios

Table 88: Cipla Limited: key facts

Table 89: Cipla Limited: key financials (USD )

Table 90: Cipla Limited: key financials (Rs.)

Table 91: Cipla Limited: key financial ratios

Table 92: Lupin Ltd: key facts

Table 93: Lupin Ltd: key financials (USD )

Table 94: Lupin Ltd: key financials (Rs.)

Table 95: Lupin Ltd: key financial ratios

Table 96: Sun Pharmaceutical Industries Ltd: key facts

Table 97: Sun Pharmaceutical Industries Ltd: key financials (USD )

Table 98: Sun Pharmaceutical Industries Ltd: key financials (Rs.)

Table 99: Sun Pharmaceutical Industries Ltd: key financial ratios

Table 100: Apotex, Inc.: key facts

Table 101: Pfizer Inc.: key facts

Table 102: Pfizer Inc.: key financials (USD )

Table 103: Pfizer Inc.: key financial ratios

Table 104: Teva Pharmaceutical Industries Limited: key facts

Table 105: Teva Pharmaceutical Industries Limited: key financials (USD )

Table 106: Teva Pharmaceutical Industries Limited: key financial ratios

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

MarketLine, Pharmaceuticals and Healthcare, Generics , Emerging Markets